Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin
- PMID: 20442307
- DOI: 10.1158/1535-7163.MCT-09-0679
Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin
Abstract
Overexpression of betaIII-tubulin is associated with resistance to tubulin-binding agents (TBA) in a range of tumor types. We previously showed that small interfering RNA silencing of betaIII-tubulin expression hypersensitized non-small cell lung cancer cells to TBAs. To determine whether betaIII-tubulin mediates its effect on drug-induced mitotic arrest and cell death by differentially regulating microtubule behavior, the effects of betaIII-tubulin knockdown on microtubule dynamics were analyzed in H460 non-small cell lung cancer cells stably expressing green fluorescent protein-betaI-tubulin. Interphase cells were examined at three vincristine and paclitaxel concentrations that (a) inhibited cell proliferation, (b) induced 5% to 10% mitotic arrest, and (c) induced 30% to 40% mitotic arrest. In the absence of either drug, betaIII-tubulin knockdown caused no significant change in microtubule dynamic instability. At 2 nmol/L vincristine (IC(50)), overall microtubule dynamicity was significantly suppressed in betaIII-tubulin knockdowns (-31.2%) compared with controls (-6.5%). Similar results were obtained with paclitaxel, suggesting that knockdown of betaIII-tubulin induces hypersensitivity by enhancing stabilization of microtubule dynamics at low drug concentrations. At higher drug concentrations (> or =40 nmol/L vincristine; > or =20 nmol/L paclitaxel), betaIII-tubulin knockdown resulted in significantly reduced suppressive effects on microtubule dynamicity with little or no further increase in mitotic arrest, compared with control cells. Importantly, apoptosis was markedly increased by betaIII-tubulin knockdown independent of further suppression of microtubule dynamics and mitotic arrest. These results show that betaIII-tubulin knockdown enhances the effectiveness of TBAs through two mechanisms: suppression of microtubule dynamics at low drug concentrations and a mitosis-independent mechanism of cell death at higher drug concentrations.
Similar articles
-
βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.Cancer Chemother Pharmacol. 2017 Jul;80(1):151-164. doi: 10.1007/s00280-017-3345-2. Epub 2017 May 31. Cancer Chemother Pharmacol. 2017. PMID: 28567478
-
BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability.J Biol Chem. 2005 Apr 1;280(13):12902-7. doi: 10.1074/jbc.M414477200. Epub 2005 Feb 6. J Biol Chem. 2005. PMID: 15695826
-
Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer.Cancer Res. 2007 Oct 1;67(19):9356-63. doi: 10.1158/0008-5472.CAN-07-0509. Cancer Res. 2007. PMID: 17909044
-
Microtubules and resistance to tubulin-binding agents.Nat Rev Cancer. 2010 Mar;10(3):194-204. doi: 10.1038/nrc2803. Epub 2010 Feb 11. Nat Rev Cancer. 2010. PMID: 20147901 Review.
-
An overview on anti-tubulin agents for the treatment of lymphoma patients.Pharmacol Ther. 2020 Jul;211:107552. doi: 10.1016/j.pharmthera.2020.107552. Epub 2020 Apr 17. Pharmacol Ther. 2020. PMID: 32305312 Review.
Cited by
-
A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule.Acta Pharmacol Sin. 2012 Feb;33(2):261-70. doi: 10.1038/aps.2011.156. Acta Pharmacol Sin. 2012. PMID: 22301862 Free PMC article.
-
Improving therapeutic synergy score predictions with adverse effects using multi-task heterogeneous network learning.Brief Bioinform. 2023 Jan 19;24(1):bbac564. doi: 10.1093/bib/bbac564. Brief Bioinform. 2023. PMID: 36562724 Free PMC article.
-
Pericyte dynamics during angiogenesis: new insights from new identities.J Vasc Res. 2014;51(3):163-74. doi: 10.1159/000362276. Epub 2014 May 17. J Vasc Res. 2014. PMID: 24853910 Free PMC article. Review.
-
Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin.Acta Pharmacol Sin. 2014 Jul;35(7):916-28. doi: 10.1038/aps.2014.33. Epub 2014 May 26. Acta Pharmacol Sin. 2014. PMID: 24858311 Free PMC article.
-
Delineating the Role of βIV-Tubulins in Pancreatic Cancer: βIVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids.Neoplasia. 2016 Dec;18(12):753-764. doi: 10.1016/j.neo.2016.10.011. Epub 2016 Nov 24. Neoplasia. 2016. PMID: 27889644 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources